Suzhou Basecare Medical Receives Landmark NMPA Approval for First Domestically Developed PGT-A Kit

Key Points of the Announcement

• Regulatory Milestone: Suzhou Basecare Medical Corporation Limited (“Basecare Medical” or “the Company”) has received national Class III medical device registration from the National Medical Products Administration (NMPA) for its pre-implantation genetic testing kit for aneuploidy (PGT-A Kit) on March 13, 2026.
• First of Its Kind in China: This PGT-A kit is the first in China to be based entirely on a domestically developed high-throughput gene sequencing platform, marking a significant technological and strategic breakthrough in the Chinese assisted reproductive technology (ART) field.
• Target Patient Groups: The kit is designed for IVF patients aged 35 and above, couples with chromosomal abnormalities, individuals who have suffered three or more failed embryo transfers or miscarriages, and families who previously had children with chromosomal abnormalities.
• Technological Innovation: The kit utilizes a probe-anchored polymerization sequencing method, offering a fully localized “equipment-reagents-analysis software” chain, enhancing China’s independence in assisted reproductive genetic testing.
• Clinical Impact: The PGT-A kit is expected to reduce the risk of miscarriage and birth defects by enabling more accurate screening of chromosomal aneuploidy in embryos, supporting third-generation IVF technology.
• Rigorous Validation: The kit underwent multi-center systematic validation for detection accuracy, platform compatibility, and clinical applicability, ensuring its reliability and robustness for clinical use.

Potential Price-Sensitive Information for Shareholders

• First-Mover Advantage: Basecare Medical is the first company in China to launch a PGT-A kit built on a purely local sequencing platform. This could significantly impact the Company’s market share and competitive positioning in the rapidly growing IVF and genetic testing markets.
• Strategic Importance: The successful development and approval of this kit fill an important gap in China’s genetic testing capabilities, potentially reducing reliance on imported technologies and supporting government initiatives to localize key medical technologies.
• Growth Catalyst: The PGT-A kit is expected to drive new revenue streams for Basecare Medical, as it offers a clinically validated, locally sourced solution for IVF centers across China. This could translate into increased adoption and sales as domestic IVF procedures continue to rise.
• Reputation and Innovation: Achieving a “Chinese chip” breakthrough in genetic testing enhances the Company’s brand and technological leadership, which may positively impact investor sentiment and share price.
• Regulatory Risk Mitigation: Full domestic development and regulatory approval reduce risks associated with foreign supply chain disruptions and regulatory hurdles, further strengthening the Company’s long-term business fundamentals.

Details for Investors

On March 13, 2026, Suzhou Basecare Medical Corporation Limited was granted the national Class III medical device registration certificate (No.: Guo Xie Zhu Zhun 20263400529) for its pre-implantation genetic testing kit for aneuploidy (PGT-A kit), which employs a probe-anchored polymerization sequencing method on a high-throughput gene sequencing platform developed entirely in China. This approval marks a pivotal moment as the first PGT-A kit in the Chinese market based solely on domestic technology.

The newly approved kit is designed for specific high-risk IVF patient populations, including women aged 35 and above, couples with chromosomal defects, patients with repeated IVF failures or recurrent miscarriages, and families with a history of chromosomal abnormalities. By analyzing DNA from embryonic cells, the PGT-A kit detects chromosomal aneuploidy, supporting clinical decision-making for embryo implantation.

This technological advancement represents a breakthrough for China’s reproductive genetics sector. It completes the full domestic localization of the “equipment-reagents-analysis software” value chain, reducing reliance on foreign technologies and strengthening the nation’s health industry with a “Chinese chip” solution.

Scientifically, the PGT-A kit is expected to lower rates of miscarriage and birth defects by improving embryo selection during IVF procedures. The kit has undergone multi-center validation, demonstrating high detection accuracy, compatibility with existing platforms, and strong clinical applicability. This solution not only addresses a critical gap in the market for locally developed PGT-A solutions but also provides IVF clinics and patients with a more independent and controllable testing option.

For investors, this development signals Basecare Medical’s enhanced competitive positioning and potential for market expansion. The Company’s first-mover status, government policy alignment, and technological innovation could all serve as catalysts for share price appreciation.

Board of Directors and Company Statement

The announcement was authorized by the Board of Directors, including Chairman and General Manager Dr. Liang Bo and other executive, non-executive, and independent non-executive directors. The Company cautions shareholders and potential investors to exercise care when trading in the Company’s shares, as the announcement contains forward-looking information and the actual impact on financial performance will depend on market adoption and future developments.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should exercise caution and conduct their own due diligence before making any investment decisions. The information is based on the Company’s voluntary announcement dated March 16, 2026, and may contain forward-looking statements subject to risks and uncertainties.

View BASECARE-B Historical chart here